Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995502 | 0.83 | NAMPT (0.65) | NAMPTNPC1RAB9ATRPV1LMNA | |
| SCHEMBL12078323 | 0.83 | NAMPT (0.71) | NAMPTFLT3AURKAKDRTRPV1 | |
| SCHEMBL996378 | 0.81 | NAMPT (0.72) | NAMPTNPC1RAB9ATRPV1MEN1 | |
| SCHEMBL995756 | 0.81 | CYP11B1 (0.69) | NAMPTTRPV1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12078113 | 0.77 | NAMPT (0.66) | NAMPTFLT3AURKATRPV1LRRK2 | |
| SCHEMBL3393246 | 0.74 | FLT3 (0.54) | NAMPTFLT3AURKAKDRNPC1 | |
| SCHEMBL12078712 | 0.73 | NAMPT (0.71) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL12078884 | 0.72 | NAMPT (0.70) | NAMPTMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL11300651 | 0.72 | NAMPT (0.59) | NAMPTTRPV1SMN1; SMN2TSHRUSP2 | |
| SCHEMBL28797316 | 0.72 | MAPT (0.69) | NPC1RAB9AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079859-B2 | Synthetic lethal targeting of glucose transport | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-14 | — | — | US | claimed |
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | claimed |
| US-20140128397-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | RUGA CORPORATION | 2014-05-08 | — | — | US | claimed |
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | AUCKLAND UNIVSERVICES LIMITED (NZ) | 2012-09-06 | — | — | US | claimed |
| WO-2012100223-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | IRWIN JOHN (US) | 2012-07-26 | — | — | WO | claimed |
| US-9079859-B2 | Synthetic lethal targeting of glucose transport | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-14 | — | — | US | disclosed |
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140128397-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | RUGA CORPORATION | 2014-05-08 | — | — | US | disclosed |
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2014-02-20 | — | — | US | disclosed |
| US-8440652-B2 | MST1 kinase inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-09-06 | — | — | US | disclosed |
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | AUCKLAND UNIVSERVICES LIMITED (NZ) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | NAMPT 1063/4885FLT3 434/4885AURKA 830/4885 |
| US-20120225862-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | BRDT, NISCH, PAICS | NAMPT 624/4885FLT3 656/4885AURKA 2838/4885 |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | NAMPT 1063/4885FLT3 434/4885AURKA 830/4885 |
| US-20140128397-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | SLC2A1, SLC2A3, SLC2A2 | NAMPT 601/4885FLT3 1113/4885AURKA 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.